Lucid dreams are frequently pleasant and training techniques have been developed to teach dreamers to induce them. In addition, the induction of lucid dreams has also been used as a way to ameliorate nightmares. On the other hand, lucid dreams may be associated with psychiatric conditions, including Post-Traumatic Stress Disorder (PTSD) and Reward Deficiency Syndrome-associated diagnoses. In the latter conditions, lucid dreams can assume an unpleasant and frequently terrifying character.
We present two cases of dramatic alleviation of terrifying lucid dreams in patients with PTSD. In the first case study, a 51-year-old, obese woman, diagnosed with PTSD and depression, had attempted suicide and experienced terrifying lucid nightmares linked to sexual/physical abuse from early childhood by family members including her alcoholic father. Her vivid “bad dreams” remained refractory in spite of 6 months of treatment with Dialectical Behavioral Therapy (DBT) and standard pharmaceutical agents which included prazosin, clonidie and Adderall. The second 39-year-old PTSD woman patient had also suffered from lucid nightmares.
The medication visit notes reveal changes in the frequency, intensity and nature of these dreams after the complex putative dopamine agonist KB220Z was added to the first patient’s regimen. The patient reported her first experience of an extended period of happy dreams. The second PTSD patient, who had suffered from lucid nightmares, was administered KB220Z to attenuate methadone withdrawal symptoms and incidentally reported dreams full of happiness and laughter.
These cases are discussed with reference to the known effects of KB220Z including enhanced dopamine homeostasis and functional connectivity of brain reward circuitry in rodents and humans. Their understanding awaits intensive investigation involving large-population, double-blinded studies.
Aurora, R. N., Zak, R. S., Auerbach, S. H., Casey, K. R., Chowduri, S., Krippot, A., Maganti, R. K., Ramar, K., Kristo, D. A., Bista, S. R., Lamm, C. I. & Morgenthaler, T. I. (2010). Standards of practice committee on treatment of nightmares. Journalof Clinical Sleep Medicine, 6, 389–401
Blum, K., Chen, A. L., Braverman, E. R., Comings, D. E., Chen, T. J., Arcuri, V., Blum, S. H., Downs, B. W., Waite, R. L., Notaro, A., Lubar, J., Williams, L., Prihoda, T. J., Palomo, T. & Oscar-Berman, M. (2008). Attention-deficit-hyperactivity disorder and reward deficiency syndrome. Journal of Neuropsychiatric Disease and Treatment, 4, 893–918
Blum, K., Chen, T. J., Morse, S., Giordano, J., Chen, A. L., Thompson, J., Allen, C., Smolen, A., Lubar, J., Stice, E., Downs, B. W., Waite, R. L., Madigan, M. A., Kerner, M., Fornari, F. & Braverman, E. R. (2010). Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D2 agonist therapy: Part 2. Postgraduate Medical Journal, 122, 214–226
Blum, K., Femino, J., Teitlebaum, S., Oscar-Berman, M., Giordano, J. & Gold, M. S. (2013). 12 steps program & fellowship:Neurobiology of recovery. New York: Springer Briefs
Blum, K., Gardner, E., Oscar-Berman, M. & Gold, M. (2012). “Liking” and “wanting” linked to Reward Deficiency Syndrome (RDS): Hypothesizing differential responsivity in brain rewardcircuitry. Current Pharmaceutical Design, 18, 113–118
Blum, K., Liu, Y., Wang, W., Wang, Y., Zhang, Y., Oscar-Berman, M., Smolen, A., Febo, M., Han, D., Simpatico, T., Cronjé, F. J., Demetrovics, Z. & Gold, M. S. (2015). rsf MRI effects of KB220Z™ on neural pathways in reward circuitry of abstinent genotyped heroin addicts. Postgraduate Medical Journal, 127(2), 232–241
Blum, K., Oscar-Berman, M., Femino, J., Waite, R. L., Benya, L., Giordano, J., Borsten, J., Downs, W. B., Braverman, E. R., Loehmann, R., Dushaj, K., Han, D., Simpatico, T., Hauser, M., Barh, D. & McLaughlin, T. J. (2013). Withdrawal from buprenorphine/naloxone and maintenance with a natural dopaminergic agonist: A cautionary note. Journal of Addiction Research and Therapy, 4(2)
Blum, K., Oscar-Berman, M., Stuller, E., Miller, D., Giordano, J., Morse, S., McCormick, L., Downs, W. B., Waite, R. L., Barh, D., Neal, D., Braverman, E. R., Lohmann, R., Borsten, J., Hauser, M., Han, D., Liu, Y., Helman, M. & Simpatico, T. (2012). Neurogenetics and nutrigenomics of neuro-nutrient therapy for Reward Deficiency Syndrome (RDS): Clinical ramifications as a function of molecular neurobiological mechanisms. Journalof Addiction Research and Therapy, 3(5), 139
Febo, M., Blum, K., Liu, Y. & Gold, M. S. (2014). Putative dopamine agonist (KB220Z) enhances resting state functional connectivity in brain reward circuitry. Presentation at Addictions Conference 2014, Aug 4–6, Chicago, USA
Fusar-Poli, P., Perez, J., Broome, M., Borgwardt, S., Placentino, A., Caverzasi, E., Cortesi, M., Veggiotti, P., Politi, P., Barale, F. & McGuire, P. (2007). Neurofunctional correlates of vulnerability to psychosis: A systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews, 31, 465–484
Gottesmann, C. (2006). The dreaming sleep stage: A new neurobiological model of schizophrenia? Neuroscience, 140, 1105–1115
Gottesmann, C. & Joncas, S. (2000). Letter to the editor: Hypothesis for the neurophysiology of dreaming. Journal of Sleep Reseach, 3, 1–4
Hinton, D. E., Peou, S., Joshi, S., Nickerson, A. & Simon, N. M. (2013). Normal grief and complicated bereavement among traumatized cambodian refugees: Cultural context and the central role of dreams of the dead. Culture, Medicine, and Psychiatry, 37, 427–464
Klinger, E. (1971). Structure and functions of fantasy. 1 st edition (p. 57). New York: Wiley Interscience
Kovachy, B., O’Hara, R., Hawkins, N., Gershon, A., Primeau, M. M., Madej, J. & Carrion, V. (2013). Sleep disturbance in pediatric PTSD: Current findings and future directions. Journal of Clinical Sleep Medicne, 9, 501–510
McLaughlin, T., Steinberg, B., Christensen, B., Law, I., Parving, A. & Friberg, L. (2014) Potential language and attentional networks revealed through factor analysis of rCBF data measured with SPECT. Journal of Cerebral Blood Flow & Metabolism, 12(4), 535–545
Mellman, T. A., David, D., Kulick-Bell, R., Hebding, J. & Nolan, B. (1995). Sleep disturbance and its relationship to psychiatric morbidity after Hurricane Andrew. The American Journal of Psychiatry, 152, 1659–1663
Nielson, T. & Levin, R. (2007). Nightmares: A new neurocognitive model. Sleep Medicine Reviews, 11, 295–310
Pearson-Fuhrhop, K. M., Dunn, E. C., Mortero, S., Devan, W. J., Falcone, G. J., Lee, P., Holmes, A. J., Hollinshead, M. O., Roffman, J. L., Smoller, J. W., Rosand, J. & Cramer, S. C. (2014) Dopamine genetic risk score predicts depressive symptoms in healthy adults and adults with depression. PLoS One, 9(5), e93772
Rosen, J., Reynolds, C. F. 3rd, Yeager, A. L., Houck, P. R. & Hurwitz, L. F. (1991). Sleep disturbances in survivors of the Nazi Holocaust. The American Journal of Psychiatry, 148, 62–66
Schredl, M., Bohusch, C., Kahl, J., Mader, A. & Somesan, A. (2000). The use of dreams in psychotherapy: A survey of psychotherapists in private practice. The Journal of Psychotherapy Practice and Research, 9, 81–87
Sil’kis, I. G. (2006). Role of the basal ganglia in the occurrence of paradoxical sleep dreams (hypothetical mechanism). Zh Vyssh Nerv Deiat Im I P Pavlova, 56, 5–21
Sil’kis, I. G. (2010.) Paradoxical sleep as a tool for understanding the hippocampal mechanisms of contextual memory. Neuroscienceand Behavioral Physiology, 40, 5–19
Solms, M. (2000). Dreaming and REM sleep are controlled by different brain mechanisms. Behavioral and Brain Sciences, 23, 843–850
Spoormaker, V. I., Schredl, M. & van den Bout, J. (2006). Nightmares: from anxiety symptom to sleep disorder. Sleep Medicine Reviews, 10, 19–31
Thompson, D. F. & Pierce, D. R. (1999). Drug-induced nightmares. Annals of Pharmacotherapy, 33, 93–98